Key Points
- Director Sue-Jean Lin sold 25,272 shares at an average price of $30.78 for a total of $777,872, leaving her with 26,735 shares—a reported 48.59% reduction in her ownership.
- Arcutis (ARQT) is trading near $30.73 (one‑year high $31.09) after reporting revenue of $99.22 million and EPS of $0.06 for the quarter, beating estimates, though the company still shows a negative net margin and return on equity.
- Analysts are mixed but overall positive with a MarketBeat consensus of "Moderate Buy" and an average price target of $28.00; the stock carries a market cap of about $3.76 billion.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Sue-Jean Lin sold 25,272 shares of the firm's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $30.78, for a total transaction of $777,872.16. Following the completion of the transaction, the director directly owned 26,735 shares of the company's stock, valued at $822,903.30. This represents a 48.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Arcutis Biotherapeutics Stock Performance
Shares of ARQT stock opened at $30.73 on Wednesday. The company has a fifty day moving average price of $22.14 and a two-hundred day moving average price of $17.38. Arcutis Biotherapeutics, Inc. has a one year low of $10.57 and a one year high of $31.09. The stock has a market cap of $3.76 billion, a P/E ratio of -85.36 and a beta of 1.97. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.50 and a quick ratio of 3.28.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.16. Arcutis Biotherapeutics had a negative net margin of 13.94% and a negative return on equity of 29.69%. The company had revenue of $99.22 million for the quarter, compared to analyst estimates of $86.69 million. As a group, equities analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ARQT. Zacks Research upgraded shares of Arcutis Biotherapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 29th. Cowen restated a "buy" rating on shares of Arcutis Biotherapeutics in a report on Thursday, August 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of Arcutis Biotherapeutics in a research note on Tuesday, October 14th. Mizuho set a $32.00 price objective on Arcutis Biotherapeutics in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group upped their target price on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a "neutral" rating in a report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Arcutis Biotherapeutics has a consensus rating of "Moderate Buy" and an average price target of $28.00.
Get Our Latest Report on Arcutis Biotherapeutics
Institutional Investors Weigh In On Arcutis Biotherapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cerity Partners LLC bought a new stake in shares of Arcutis Biotherapeutics during the 1st quarter valued at $303,000. CWM LLC increased its position in shares of Arcutis Biotherapeutics by 88.9% during the first quarter. CWM LLC now owns 11,331 shares of the company's stock valued at $177,000 after buying an additional 5,333 shares during the period. Kestra Private Wealth Services LLC purchased a new stake in shares of Arcutis Biotherapeutics in the first quarter worth about $221,000. Royce & Associates LP purchased a new stake in shares of Arcutis Biotherapeutics in the first quarter worth about $4,185,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Arcutis Biotherapeutics by 3.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,697 shares of the company's stock valued at $464,000 after acquiring an additional 917 shares during the period.
Arcutis Biotherapeutics Company Profile
(
Get Free Report)
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
